Summary
Global Markets Direct’s, ‘Guillain-Barre Syndrome - Pipeline Review, H1 2016’, provides an overview of the Guillain-Barre Syndrome pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Guillain-Barre Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Guillain-Barre Syndrome and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Guillain-Barre Syndrome
- The report reviews pipeline therapeutics for Guillain-Barre Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Guillain-Barre Syndrome therapeutics and enlists all their major and minor projects
- The report assesses Guillain-Barre Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Guillain-Barre Syndrome
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Guillain-Barre Syndrome
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Guillain-Barre Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Akari Therapeutics, Plc
Alexion Pharmaceuticals, Inc.
Regenesance BV
Takeda Pharmaceutical Company Limited
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Guillain-Barre Syndrome Overview 6
Therapeutics Development 7
Pipeline Products for Guillain-Barre Syndrome - Overview 7
Pipeline Products for Guillain-Barre Syndrome - Comparative Analysis 8
Guillain-Barre Syndrome - Therapeutics under Development by Companies 9
Guillain-Barre Syndrome - Therapeutics under Investigation by Universities/Institutes 10
Guillain-Barre Syndrome - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Guillain-Barre Syndrome - Products under Development by Companies 14
Guillain-Barre Syndrome - Products under Investigation by Universities/Institutes 15
Guillain-Barre Syndrome - Companies Involved in Therapeutics Development 16
Akari Therapeutics, Plc 16
Alexion Pharmaceuticals, Inc. 17
Regenesance BV 18
Takeda Pharmaceutical Company Limited 19
Guillain-Barre Syndrome - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
Coversin - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
eculizumab - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
immune globulin (human) - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
immune globulin (human) - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Peptide for Cholera and Guillain-Barre Syndrome - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecule to Inhibit C6 for Guillain-Barre Syndrome - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Guillain-Barre Syndrome - Recent Pipeline Updates 40
Guillain-Barre Syndrome - Dormant Projects 48
Guillain-Barre Syndrome - Product Development Milestones 49
Featured News & Press Releases 49
Jan 29, 2016: Akari Therapeutics Receives Approval From the UK Medicines & Healthcare Products Regulatory Agency for Phase IB Multiple Ascending Dose Trial 49
Jan 05, 2016: Akari Therapeutics Announces Additional Data from Non-Human Primate Safety Study Demonstrating Equivalent Coversin Efficacy in Both Elisa CH50 and Hemolytic SRBC Assays 49
Dec 07, 2015: Akari Therapeutics Announces Update From Non-Human Primate Safety Study at International PNH Interest Group 10th Annual Scientific Meeting 50
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 52
Disclaimer 53
List of Tables
Number of Products under Development for Guillain-Barre Syndrome, H1 2016 7
Number of Products under Development for Guillain-Barre Syndrome - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Number of Products under Investigation by Universities/Institutes, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Development, H1 2016 13
Products under Development by Companies, H1 2016 14
Products under Investigation by Universities/Institutes, H1 2016 15
Guillain-Barre Syndrome - Pipeline by Akari Therapeutics, Plc, H1 2016 16
Guillain-Barre Syndrome - Pipeline by Alexion Pharmaceuticals, Inc., H1 2016 17
Guillain-Barre Syndrome - Pipeline by Regenesance BV, H1 2016 18
Guillain-Barre Syndrome - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 19
Assessment by Monotherapy Products, H1 2016 20
Number of Products by Stage and Target, H1 2016 22
Number of Products by Stage and Mechanism of Action, H1 2016 24
Number of Products by Stage and Route of Administration, H1 2016 26
Number of Products by Stage and Molecule Type, H1 2016 28
Guillain-Barre Syndrome Therapeutics - Recent Pipeline Updates, H1 2016 40
Guillain-Barre Syndrome - Dormant Projects, H1 2016 48
List of Figures
Number of Products under Development for Guillain-Barre Syndrome, H1 2016 7
Number of Products under Development for Guillain-Barre Syndrome - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Number of Products under Investigation by Universities/Institutes, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Products, H1 2016 13
Assessment by Monotherapy Products, H1 2016 20
Number of Products by Targets, H1 2016 21
Number of Products by Stage and Targets, H1 2016 21
Number of Products by Mechanism of Actions, H1 2016 23
Number of Products by Stage and Mechanism of Actions, H1 2016 23
Number of Products by Routes of Administration, H1 2016 25
Number of Products by Stage and Routes of Administration, H1 2016 25
Number of Products by Molecule Types, H1 2016 27
Number of Products by Stage and Molecule Types, H1 2016 27
